Date of implant, estimated.Exemption number (b)(4) permits numbering sequence to begin with 10000, to avoid duplication of report numbers due to process transition.There may be gaps in numbering for reports submitted during the transition period.The scaffold remains in the patient.Investigation is not yet complete.A follow-up report will be submitted with all additional relevant information.Na.
|
It was reported that approximately 3 years post absorb bioresorbable vascular scaffold (bvs) implantation in the right coronary artery, the patient may have experienced angina.On (b)(6) 2019, optical coherence tomography (oct) was performed, and it was noted that the bvs had not yet been resorbed and restenosis was seen.Angioplasty was performed using a drug eluting balloon to treat the restenosis.No additional information was provided.
|
D4: the unique device identifier (udi) is unknown because the part and lot numbers were not provided.The device was not returned for evaluation.A review of the lot history record and complaint history could not be conducted because the part and lot numbers were not provided.The reported patient effects of angina and stenosis are listed in the bioresorbable vascular scaffold (bvs) system, absorb, instructions for use (ifu) as known adverse events associated with the use of a coronary scaffold in native coronary arteries.The investigation determined the reported complaint, additional treatment and hospitalization appear to be related to operational context.A conclusive cause for the reported patient effects and the relationship to the product, if any, cannot be determined.There is no indication of a product quality issue with respects to the design, manufacture, or labeling of the device.Device code 1506 - removed.
|